Epidemics and Public Goods

from Business and policy through an Economist’s Lens at http://bit.ly/1xgIbhA on December 31, 2014 at 06:18PM In a recent article about Ebola in the Wall Street Journal, Peter Piot, the Director of the London School of Tropical Medicine & Hygiene, referred to epidemics like Ebola as what economists refer to as a public good.  For […]

Homegrown bioterror

from The Incidental Economist at http://bit.ly/13S8XS0 on December 31, 2014 at 01:08PM Conventional wisdom says “superbugs” emerge in places like India or Africa and move to the US through global travel. That was certainly the case with the Ebola virus recently and the NDM-1 bacteria from India. However, an interesting research letter in Nature Genetics […]

Does your mortality rate increase when your doctor is out of town?

from Healthcare Economist at http://bit.ly/1A75dYd on December 30, 2014 at 07:42AM According to a paper by Jena et al. (2014), the answer is no. The paper examines 30-day mortality rates for Medicare patients admitted to the hospital with acute myocardial infarction (AMI) or heart failure and compares “…mortality and treatment differences…during dates of national cardiology […]

Crystal Clear? The Relationship Between Methamphetamine Use and Sexually Transmitted Infections

from Health Economics at http://bit.ly/1tfNloV on December 29, 2014 at 10:12AM Public health officials have cited methamphetamine control as a tool with which to decrease HIV and other sexually transmitted infections, based on previous research that finds a strong positive correlation between methamphetamine use and risky sexual behavior. However, the observed correlation may not be […]

A Systematic Review on Cost Effectiveness of HIV Prevention Interventions in the United States

from Latest Results for Applied Health Economics and Health Policy at http://bit.ly/1wF4RrW on December 25, 2014 Abstract Background The Centers for Disease Control and Prevention (CDC) focus on funding HIV prevention interventions likely to have high impact on the HIV epidemic. In its most recent funding announcement to state and local health department grantees, CDC […]

Potential Savings in Prescription Drug Costs for Hypertension, Hyperlipidemia, and Diabetes Mellitus by Equivalent Drug Substitution in Austria: A Nationwide Cohort Study

from Latest Results for Applied Health Economics and Health Policy at http://bit.ly/1wF4QUU on December 24, 2014 Abstract Background Healthcare systems spend considerable proportions of their budgets on pharmaceutical treatment of hypertension, hyperlipidemia, and diabetes mellitus. From data on almost all residents of Austria, a country with mandatory health insurance and universal health coverage, we estimated […]


from Health Economics at http://bit.ly/1sWxI5O on December 23, 2014 at 08:28AM Life-saving medical technologies result in additional demand for health care due to increased life expectancy. However, most economic evaluations do not include all medical costs that may result from this additional demand in health care and include only future costs of related illnesses. Although […]